Adverse Event Management in Colorectal Cancer: Optimizing Treatment Approaches in the 3L Setting : Episode 9

Opinion

Video

April 25, 2024

FRESCO-2: Fruquintinib in Patients with Refractory Metastatic CRC

Arvind N. Dasari, MD, MS, provides a comprehensive overview of the FRESCO-2 trial investigating fruquintinib in patients with refractory metastatic colorectal cancer.

EP: 1.Adverse Event Management in Colorectal Cancer: Optimizing Treatment Approaches in the 3L Setting

EP: 2.Selecting Optimal 3L Colorectal Cancer Treatment

EP: 3.Patient Case 1: 46-Year-Old Woman with Prior Hx of MSS pT4aN1b Rectosigmoid Colon Adenocarcinoma s/p Prior Treatment

EP: 4.General Approach to 3L CRC Treatment with TAS-102 + Bevacizumab

EP: 5.Adverse Events Associated With TAS-102 Plus Bevacizumab in CRC

EP: 6.Patient Case 2: A 62-Year-Old Woman with Metastatic Rectal Cancer

EP: 7.Treatment Considerations With Regorafenib in Colorectal Cancer

EP: 8.Patient Case 3: A 57-Year-Old Man With Cecal Colon Adenocarcinoma

Now Viewing

EP: 9.FRESCO-2: Fruquintinib in Patients with Refractory Metastatic CRC

EP: 10.Monitoring and AE Management Strategies with Fruquintinib in CRC

EP: 11.Toxicity Considerations and Treatment Decisions in CRC

EP: 12.Multidisciplinary Care for Patients with CRC

EP: 13.Unmet Needs and Future Perspectives in Colorectal Cancer

Related Content

Squamous cell anal carcinoma | Image Credit: © Anatomy Insider - stock.adobe.com

December 20th 2024

Filling Unmet Needs in SCAC Is Key as Incidence Rates Are Rising

September 11th 2024

Oncology Experts Preview Top Abstracts From the 2024 ESMO Congress

December 18th 2024

FDA Grants Breakthrough Therapy Designation to Dostarlimab for dMMR/MSI-H Rectal Cancer

Stephen Liu, MD; Sara A. Hurvitz, MD, FACP; S. Vincent Rajkumar, MD; Sumanta Kumar Pal, MD, FASCO; Shubham Pant, MD, MBBS

May 23rd 2024

Oncology Experts Preview Top Abstracts From the 2024 ASCO Annual Meeting

Michael J. Pishvaian, MD, PhD, director, Gastrointestinal, Developmental Therapeutics and Clinical Research Programs, associate professor of Oncology, Johns Hopkins Medicine

December 13th 2024

Biomarker-Guided Treatment Approaches Transform Lung and GI Cancer Management

December 4th 2024

FDA Grants Accelerated Approval to Zenocutuzumab for NRG1+ NSCLC and Pancreatic Adenocarcinoma